Home › Compare › NPSTF vs ABBV
NPSTF yields 5.00% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, NPSTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NPSTF + ABBV for your $10,000?
Nippon Steel Trading Corporation markets and imports/exports steel, industrial supply and infrastructure, textiles, foodstuffs, and other products in Japan and internationally. The company operates through four segments: Steel, Industrial Supply and Infrastructure, Textiles, and Foodstuffs. Its steel products comprise steel sheets, steel pipes and tubes, structural steels, special steel, rods and bars, construction and raw materials, and machinery, as well as other steel, stainless steel, and titanium products. The company also offers industrial supply and infrastructure products, such as machinery and facilities for steel production, general industrial machinery, cast and forged steel products, railroad car components, automotive parts, nonferrous raw materials, nonferrous milled products, and carbon fiber products. In addition, it develops, operates, and sells industrial parks; generates and supplies electric power; and provides water supply and drainage systems. Further, the company offers textile related products and materials. Additionally, it provides foodstuffs that include processed meat products comprising beef, pork, chicken, etc.; processed fishery products, such as shrimp, crab, etc.; agricultural products and processed foods; and other foodstuffs and processed foods. Nippon Steel Trading Corporation was incorporated in 1977 and is headquartered in Tokyo, Japan.
Full NPSTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.